CTOs on the Move

Zucara Therapeutics

www.zucara.ca

 
Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.zucara.ca
  • 4th Floor 2405 Wesbrook Mall
    Vancouver, BC CAN V6T 1Z3
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Zucara Therapeutics raised $21M on 03/31/2020

Similar Companies

Ventria BioScience

Ventria BioScience is a Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lipomics Technologies

Lipomics Technologies is a West Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Moderna

Learn how we’re changing the world of medicine. Discover career opportunities, our product pipeline, and browse media resources. Meet Moderna.

Aspen Neuroscience

Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson`s disease (PD) and extending across the brain and affected organs.

Enzyvant

Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.